{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:19:50Z","timestamp":1788142790694,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82274023, 82573658, 82373135, 82474001, 82371687"],"award-info":[{"award-number":["No. 82274023, 82573658, 82373135, 82474001, 82371687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["No. CSTB2024NSCQ-MSX0444, CSTB2025NSCQ-GPX038"],"award-info":[{"award-number":["No. CSTB2024NSCQ-MSX0444, CSTB2025NSCQ-GPX038"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases","award":["KY2025004"],"award-info":[{"award-number":["KY2025004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04656-z","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:53:13Z","timestamp":1781866393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomimetic fusion nanosystem from ginger exosomes and tumor cell membranes: boosting PLK1-targeted therapy in BRCA-heterogeneous HGSOC"],"prefix":"10.1186","volume":"24","author":[{"given":"Xue","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"4656_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, B\u00f6hm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668\u201379.","journal-title":"Nat Rev Cancer"},{"key":"4656_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237\u201349.","journal-title":"Virchows Arch"},{"key":"4656_CR3","first-page":"280","volume":"69","author":"Anonymous","year":"2019","unstructured":"Anonymous. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"4656_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"4656_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45:1127\u201333.","journal-title":"Nat Genet"},{"key":"4656_CR6","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376\u201388.","journal-title":"Lancet"},{"key":"4656_CR7","doi-asserted-by":"publisher","first-page":"102103","DOI":"10.1016\/j.ctrv.2020.102103","volume":"90","author":"A Semertzidou","year":"2020","unstructured":"Semertzidou A, Brosens JJ, McNeish I, Kyrgiou M. Organoid models in gynaecological oncology research. Cancer Treat Rev. 2020;90:102103.","journal-title":"Cancer Treat Rev"},{"key":"4656_CR8","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"4656_CR9","doi-asserted-by":"publisher","first-page":"114222","DOI":"10.1016\/j.jconrel.2025.114222","volume":"387","author":"T Huang","year":"2025","unstructured":"Huang T, Huang W, Bian Q. Organoids as Predictive Platforms: Advancing Disease Modeling, Therapeutic Innovation, and Drug Delivery Systems. J Control Release. 2025;387:114222.","journal-title":"J Control Release"},{"key":"4656_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172:373\u2013e38610.","journal-title":"Cell"},{"key":"4656_CR11","doi-asserted-by":"publisher","first-page":"1702273","DOI":"10.3389\/fphar.2025.1702273","volume":"16","author":"X Shen","year":"2025","unstructured":"Shen X, Wang J, Chen S, Zhang H, Zhou C, Bae-Jump VL. Clinical relevance of PLK1 in epithelial ovarian cancer. Front Pharmacol. 2025;16:1702273.","journal-title":"Front Pharmacol"},{"key":"4656_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1126\/science.ado5178","volume":"385","author":"D Conti","year":"2024","unstructured":"Conti D, Verza AE, Pesenti ME, Cmentowski V, Vetter IR, Pan D, Musacchio A. Role of protein kinase PLK1 in the epigenetic maintenance of centromeres. Science. 2024;385:1091\u20137.","journal-title":"Science"},{"key":"4656_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.canlet.2014.12.023","volume":"357","author":"M Choi","year":"2015","unstructured":"Choi M, Kim W, Cheon MG, Lee CW, Kim JE. Polo-like kinase 1 inhibitor Bi2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. Cancer Lett. 2015;357:591\u2013601.","journal-title":"Cancer Lett"},{"issue":"7","key":"4656_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/JTO.0b013e3181d95dd4","volume":"5","author":"M Sebastian","year":"2010","unstructured":"Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J. The efficacy and safety of Bi2536, a novel Plk-1 inhibitor, in patients with stage IIIB\/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol. 2010;5(7):1060\u20137.","journal-title":"J Thorac Oncol"},{"issue":"15suppl","key":"4656_CR15","doi-asserted-by":"publisher","first-page":"14547","DOI":"10.1200\/jco.2008.26.15_suppl.14547","volume":"26","author":"HS Pandha","year":"2008","unstructured":"Pandha HS, Protheroe A, Wylie J, Parker C, Chambers J, Bell S, Munzert G. An open label phase II trial of Bi2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol. 2008;26(15suppl):14547.","journal-title":"J Clin Oncol"},{"issue":"15suppl","key":"4656_CR16","doi-asserted-by":"publisher","first-page":"8030","DOI":"10.1200\/jco.2008.26.15_suppl.8030","volume":"26","author":"J Von Pawel","year":"2008","unstructured":"Von Pawel J, Reck M, Digel W, Kortsik C, Thomas M, Frickhofen N, Schuler M, Gaschler-Markefski B, Hanft G, Sebastian M. Randomized phase II trial of two dosing schedules of Bi2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol. 2008;26(15suppl):8030.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4656_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/bjc.2012.257","volume":"107","author":"K Mross","year":"2012","unstructured":"Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME. A randomised phase II trial of the polo-like kinase inhibitor Bi2536 in chemo-na\u00efve patients with unresectable exocrine adenocarcinoma of the pancreas\u2014a study within the central european society anticancer drug research (CESAR) collaborative network. Br J Cancer. 2012;107(2):280\u20136.","journal-title":"Br J Cancer"},{"issue":"8","key":"4656_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","volume":"5","author":"G Sulli","year":"2019","unstructured":"Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 2019;5(8):475\u201394.","journal-title":"Trends Cancer"},{"issue":"9","key":"4656_CR19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.tips.2018.07.003","volume":"39","author":"G Sulli","year":"2018","unstructured":"Sulli G, Manoogian ENC, Taub PR, Panda S. Training the circadian clock, clocking the drugs, and drugging the clock to prevent, manage, and treat chronic diseases. Trends Pharmacol Sci. 2018;39(9):812\u201327.","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"4656_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"5","key":"4656_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41416-024-02704-9","volume":"131","author":"A Karabou\u00e9","year":"2024","unstructured":"Karabou\u00e9 A, Innominato PF, Wreglesworth NI, Duchemann B, Adam R, L\u00e9vi FA. Why does circadian timing of administration matter for immune checkpoint inhibitors\u2019 efficacy? Br J Cancer. 2024;131(5):783\u201396.","journal-title":"Br J Cancer"},{"issue":"12","key":"4656_CR22","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","volume":"22","author":"DC Qian","year":"2021","unstructured":"Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul\u2013Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, Lawson DH, Khan MK, Kudchadkar RR, Buchwald ZS. Effect of immunotherapy time\u2013of\u2013day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score\u2013matched analysis of a single\u2013centre, longitudinal study. Lancet Oncol. 2021;22(12):1777\u201386.","journal-title":"Lancet Oncol"},{"key":"4656_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s12951-025-03602-9","volume":"23","author":"KM Tembo","year":"2025","unstructured":"Tembo KM, Wang X, Bolideei M, et al. Exploring the bioactivity of MicroRNAs Originated from Plant-derived Exosome-like Nanoparticles (PELNs): current perspectives. J Nanobiotechnol. 2025;23:563.","journal-title":"J Nanobiotechnol"},{"key":"4656_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12951-025-03096-5","volume":"23","author":"R Han","year":"2025","unstructured":"Han R, Zhou D, Ji N, et al. Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway. J Nanobiotechnol. 2025;23:41.","journal-title":"J Nanobiotechnol"},{"key":"4656_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12951-023-02161-1","volume":"21","author":"S Li","year":"2023","unstructured":"Li S, Zhang R, Wang A, Li Y, Zhang M, Kim J, Zhu Y, Wang Q, Zhang Y, Wei Y, Wang J. Panax notoginseng\u2013derived exosome\u2013like nanoparticles attenuate ischemia reperfusion injury via altering microglia polarization. J Nanobiotechnol. 2023;21:416.","journal-title":"J Nanobiotechnol"},{"key":"4656_CR26","first-page":"82","volume":"46","author":"F Wang","year":"2024","unstructured":"Wang F, Li LY, Deng JY, Ai JC, Mo S, Ding DD, Xiao YX, Hu S, Zhu D, Li QS, Zeng Y, Chen ZT, Cheng K, Li ZH. Lipidomic analysis of plant\u2013derived extracellular vesicles for guidance of potential anti\u2013cancer therapy. Bioact Mater. 2024;46:82\u201396.","journal-title":"Bioact Mater"},{"key":"4656_CR27","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.7150\/thno.65427","volume":"12","author":"K Sundaram","year":"2022","unstructured":"Sundaram K, Mu J, Kumar A, Behera J, Lei C, Sriwastva MK, Xu F, Dryden GW, Zhang L, Chen SY, Yan J, Zhang X, Park JW, Merchant ML, Tyagi N, Teng Y, Zhang HG. Garlic exosome\u2013like nanoparticles reverse high\u2013fat diet\u2013induced obesity via the gut\/brain axis. Theranostics. 2022;12:1220\u201346.","journal-title":"Theranostics"},{"key":"4656_CR28","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.isci.2020.101571","volume":"23","author":"C Lei","year":"2020","unstructured":"Lei C, Mu J, Teng Y, He L, Xu F, Zhang X, Sundaram K, Kumar A, Sriwastva MK, Lawrenz MB, Zhang L, Yan J, Feng W, McClain CJ, Zhang X, Zhang HG. Lemon exosome\u2013like nanoparticles\u2013manipulated probiotics protect mice from C. diff infection. iScience. 2020;23:101571.","journal-title":"iScience"},{"key":"4656_CR29","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1002\/anie.201712027","volume":"57","author":"LS Lin","year":"2018","unstructured":"Lin LS, Song J, Song L, Ke K, Liu Y, Zhou Z, Shen Z, Li J, Yang Z, Tang W, Niu G, Yang HH, Chen X. Simultaneous Fenton\u2013like ion delivery and glutathione depletion by MnO\u2082\u2013based nanoagent to enhance chemodynamic therapy. Angew Chem Int Ed Engl. 2018;57:4902\u20136.","journal-title":"Angew Chem Int Ed Engl"},{"key":"4656_CR30","doi-asserted-by":"publisher","first-page":"e2500337","DOI":"10.1002\/adma.202500337","volume":"37","author":"B Liu","year":"2025","unstructured":"Liu B, Chen X, Zhu Y, Chen H, Tan J, Yang Z, Li J, Zheng P, Feng L, Wang Q, Gai S, Zhong L, Yang P, Cheng Z, Lin J. One\u2013step symbiosis of bimetallic peroxides nanoparticles to induce ferroptosis\/cuproptosis and activate cGAS\u2013STING pathway for enhanced tumor immunotherapy. Adv Mater. 2025;37:e2500337.","journal-title":"Adv Mater"},{"key":"4656_CR31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41556-019-0360-z","volume":"21","author":"M Boretto","year":"2019","unstructured":"Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B, Heremans R, Perneel L, Kobayashi H, Van Zundert I, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019;21:1041\u201351.","journal-title":"Nat Cell Biol"},{"key":"4656_CR32","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1309\/2T1Y-7BB7-DAPE-PQ6L","volume":"117","author":"HP Cathro","year":"2002","unstructured":"Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol. 2002;117:944\u201351.","journal-title":"Am J Clin Pathol"},{"key":"4656_CR33","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41467-025-56746-5","volume":"16","author":"V von Glasenapp","year":"2025","unstructured":"von Glasenapp V, Almeida AC, Chang D, Gasic I, Winssinger N, Gotta M. Spatio-temporal control of mitosis using light via a PLK1 inhibitor caged for activity and cellular permeability. Nat Commun. 2025;16:1599.","journal-title":"Nat Commun"},{"key":"4656_CR34","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12967-025-06740-8","volume":"23","author":"J Zhang","year":"2025","unstructured":"Zhang J, Li Z, Xie MY, Wang N, Liu H, Li F, Pang LJ, Qi Y. Overexpression of oncogenic polo-like kinase 1 disrupts the invasiveness, cell cycle, and apoptosis in synovial sarcoma. J Transl Med. 2025;23:691.","journal-title":"J Transl Med"},{"key":"4656_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.cub.2006.12.037","volume":"17","author":"M Steegmaier","year":"2007","unstructured":"Steegmaier M, Hoffmann M, Baum A, L\u00e9n\u00e1rt P, Petronczki M, Krss\u00e1k M, G\u00fcrtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ. Bi2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 2007;17:316\u201322.","journal-title":"Curr Biol"},{"key":"4656_CR36","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.7150\/jca.33110","volume":"11","author":"Z Li","year":"2020","unstructured":"Li Z, Yang C, Li X, Du X, Tao Y, Ren J, Fang F, Xie Y, Li M, Qian G, Xu L, Cao X, Wu Y, Lv H, Hu S, Lu J, Pan J. The dual role of Bi2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells. J Cancer. 2020;11:3274\u201387.","journal-title":"J Cancer"},{"key":"4656_CR37","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2174\/1871520619666190301145637","volume":"19","author":"HY Li","year":"2019","unstructured":"Li HY, Luo F, Li XY, Fu XF, He JF, Tian YZ, Zhu JJ, Chu XY, Zhao HL. Inhibition of polo-like kinase 1 by Bi2536 reverses the multidrug resistance of human hepatoma cells in vitro and in vivo. Anticancer Agents Med Chem. 2019;19:740\u20139.","journal-title":"Anticancer Agents Med Chem"},{"key":"4656_CR38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ebiom.2019.02.012","volume":"41","author":"M Wu","year":"2019","unstructured":"Wu M, Wang Y, Yang D, Gong Y, Rao F, Liu R, Danna Y, Li J, Fan J, Chen J, Zhang W, Zhan Q. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine. 2019;41:244\u201355.","journal-title":"EBioMedicine"},{"key":"4656_CR39","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1038\/s41467-025-60904-0","volume":"16","author":"RM Mello","year":"2025","unstructured":"Mello RM, Gomez Ceballos D, Sandate CR, Wang S, Jouffe C, Agudelo D, Uhlenhaut NH, Thom\u00e4 NH, Simon MC, Lamia KA. BMAL1 and ARNT enable circadian HIF2\u03b1 responses in clear cell renal cell carcinoma. Nat Commun. 2025;16:5834.","journal-title":"Nat Commun"},{"key":"4656_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cell.2007.04.015","volume":"129","author":"T Hunt","year":"2007","unstructured":"Hunt T, Sassone-Corsi P. Riding tandem: Circadian clocks and the cell cycle. Cell. 2007;129:461\u20134.","journal-title":"Cell"},{"key":"4656_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1126\/science.1086271","volume":"302","author":"T Matsuo","year":"2003","unstructured":"Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255\u20139.","journal-title":"Science"},{"key":"4656_CR42","doi-asserted-by":"publisher","first-page":"104321","DOI":"10.1016\/j.psj.2024.104321","volume":"103","author":"P Wang","year":"2024","unstructured":"Wang P, Li F, Sun Y, Li Y, Xie X, Du X, Liu L, Wu Y, Song D, Xiong H, Chen J, Li X. Novel insights into the circadian modulation of lipid metabolism in chicken livers revealed by RNA sequencing and weighted gene co-expression network analysis. Poult Sci. 2024;103:104321.","journal-title":"Poult Sci"},{"key":"4656_CR43","doi-asserted-by":"publisher","first-page":"111314","DOI":"10.1016\/j.bios.2019.05.019","volume":"138","author":"X Zhang","year":"2019","unstructured":"Zhang X, Hu Y, Yang X, Tang Y, Han S, Kang A, Deng H, Chi Y, Zhu D, Lu Y. F\u00f6rster resonance energy transfer (FRET)-based biosensors for biological applications. Biosens Bioelectron. 2019;138:111314.","journal-title":"Biosens Bioelectron"},{"key":"4656_CR44","doi-asserted-by":"publisher","first-page":"20255","DOI":"10.1039\/c1cp21366k","volume":"13","author":"D Tan","year":"2011","unstructured":"Tan D, Ma Z, Xu B, Dai Y, Ma G, He M, Jin Z, Qiu J. Surface passivated silicon nanocrystals with stable luminescence synthesized by femtosecond laser ablation in solution. Phys Chem Chem Phys. 2011;13:20255\u201361.","journal-title":"Phys Chem Chem Phys"},{"key":"4656_CR45","doi-asserted-by":"publisher","first-page":"8508","DOI":"10.1002\/anie.201402710","volume":"53","author":"J Masa","year":"2014","unstructured":"Masa J, Xia W, Sinev I, Zhao A, Sun Z, Gr\u00fctzke S, Weide P, Muhler M, Schuhmann W. Mn(x)O(y)\/NC and Co(x)O(y)\/NC nanoparticles embedded in a nitrogen-doped carbon matrix for high-performance bifunctional oxygen electrodes. Angew Chem Int Ed Engl. 2014;53:8508\u201312.","journal-title":"Angew Chem Int Ed Engl"},{"key":"4656_CR46","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, B\u00f6hm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668\u201379.","journal-title":"Nat Rev Cancer"},{"key":"4656_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40364-024-00632-7","volume":"12","author":"HY Ju","year":"2024","unstructured":"Ju HY, Youn SY, Kang J, Whang MY, Choi YJ, Han MR. Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer. Biomark Res. 2024;12:80.","journal-title":"Biomark Res"},{"key":"4656_CR48","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13048-024-01556-4","volume":"17","author":"KM Carey","year":"2024","unstructured":"Carey KM, Young CD, Clark AJ, Dammer EB, Singh R, Lillard JW. Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high-grade serous ovarian cancer subtype linkage to variable immune microenvironment. J Ovarian Res. 2024;17:240.","journal-title":"J Ovarian Res"},{"key":"4656_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s43046-022-00104-9","volume":"34","author":"M Khashaba","year":"2022","unstructured":"Khashaba M, Fawzy M, Abdel-Aziz A, Eladawei G, Nagib R. Subtyping of high-grade serous ovarian carcinoma: histopathological and immunohistochemical approach. J Egypt Natl Canc Inst. 2022;34:6.","journal-title":"J Egypt Natl Canc Inst"},{"key":"4656_CR50","doi-asserted-by":"publisher","first-page":"985187","DOI":"10.3389\/fimmu.2022.985187","volume":"13","author":"Y Ren","year":"2022","unstructured":"Ren Y, Li R, Feng H, Xie J, Gao L, Chu S, Li Y, Meng FL, Ning YS. Single-cell sequencing reveals effects of chemotherapy on the immune landscape and TCR\/BCR clonal expansion in a relapsed ovarian cancer patient. Front Immunol. 2022;13:985187.","journal-title":"Front Immunol"},{"key":"4656_CR51","doi-asserted-by":"publisher","first-page":"104001","DOI":"10.1016\/j.ebiom.2022.104001","volume":"79","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Bi M, Guo H, Li M. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis. EBioMedicine. 2022;79:104001.","journal-title":"EBioMedicine"},{"key":"4656_CR52","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/jmcb\/mjz051","volume":"12","author":"X Liu","year":"2020","unstructured":"Liu X, Xu L, Li J, Yao PY, Wang W, Ismail H, Wang H, Liao B, Yang Z, Ward T, Ruan K, Zhang J, Wu Q, He P, Ding X, Wang D, Fu C, Dou Z, Yan F, Wang W, Liu X, Yao X. Mitotic motor CENP-E cooperates with PRC1 in temporal control of central spindle assembly. J Mol Cell Biol. 2020;12:654\u201365.","journal-title":"J Mol Cell Biol"},{"key":"4656_CR53","doi-asserted-by":"publisher","first-page":"e2316731121","DOI":"10.1073\/pnas.2316731121","volume":"121","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wu G, Sancar A, Hogenesch JB. Mutations of the circadian clock genes Cry, Per, or Bmal1 have different effects on the transcribed and nontranscribed strands of cycling genes. Proc Natl Acad Sci. 2024;121:e2316731121.","journal-title":"Proc Natl Acad Sci"},{"key":"4656_CR54","doi-asserted-by":"publisher","first-page":"8250","DOI":"10.1038\/s41467-025-63778-4","volume":"16","author":"A Gallardo","year":"2025","unstructured":"Gallardo A, Belmonte-Reche E, Marti-Marimon M, Domingo-Rein\u00e9s J, Peris G, L\u00f3pez-Onieva L, Fern\u00e1ndez-Rengel I, Xie J, Trist\u00e1n-Ramos P, Bellora N, S\u00e1nchez-Pozo A, Est\u00e9vez AM, Heras SR, Marti-Renom MA, Landeira D. BMAL1-TRIM28 represses transposable elements independently of CLOCK in pluripotent cells. Nat Commun. 2025;16:8250.","journal-title":"Nat Commun"},{"key":"4656_CR55","doi-asserted-by":"publisher","first-page":"e170998","DOI":"10.1172\/JCI170998","volume":"134","author":"LA Schrader","year":"2024","unstructured":"Schrader LA, Ronnekleiv-Kelly SM, Hogenesch JB, Bradfield CA, Mc Malecki K. Circadian disruption, clock genes, and metabolic health. J Clin Invest. 2024;134:e170998.","journal-title":"J Clin Invest"},{"key":"4656_CR56","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-022-31715-4","volume":"13","author":"Y An","year":"2022","unstructured":"An Y, Yuan B, Xie P, Gu Y, Liu Z, Wang T, Li Z, Xu Y, Liu Y. Decoupling PER phosphorylation, stability and rhythmic expression from circadian clock function by abolishing PER-CK1 interaction. Nat Commun. 2022;13:3991.","journal-title":"Nat Commun"},{"key":"4656_CR57","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nsmb.3076","volume":"22","author":"AG Tamayo","year":"2015","unstructured":"Tamayo AG, Duong HA, Robles MS, Mann M, Weitz CJ. Histone monoubiquitination by Clock-Bmal1 complex marks Per1 and Per2 genes for circadian feedback. Nat Struct Mol Biol. 2015;22:759\u201366.","journal-title":"Nat Struct Mol Biol"},{"key":"4656_CR58","doi-asserted-by":"publisher","first-page":"e2412227","DOI":"10.1002\/adma.202412227","volume":"36","author":"Z Hu","year":"2024","unstructured":"Hu Z, Tan H, Ye Y, Xu W, Gao J, Liu L, Zhang L, Jiang J, Tian H, Peng F, Tu Y. NIR-actuated ferroptosis nanomotor for enhanced tumor penetration and therapy. Adv Mater. 2024;36:e2412227.","journal-title":"Adv Mater"},{"issue":"10","key":"4656_CR59","doi-asserted-by":"publisher","first-page":"16286","DOI":"10.1021\/acsnano.1c05451","volume":"15","author":"YD Guo","year":"2021","unstructured":"Guo YD, Xu YY, Bao QQ, Shen C, Ni DL, Hu P, Shi JL. Endogenous Copper for Nanocatalytic Oxidative Damage and Self-Protection Pathway Breakage of Cancer. ACS Nano. 2021;15(10):16286\u201397.","journal-title":"ACS Nano"},{"issue":"44","key":"4656_CR60","doi-asserted-by":"publisher","first-page":"24153","DOI":"10.1021\/jacs.3c08032","volume":"145","author":"QS Feng","year":"2023","unstructured":"Feng QS, Fang WM, Guo YD, Hu P, Shi JL. Nebulized Therapy of Early Orthotopic Lung Cancer by Iron-Based Nanoparticles: Macrophage-Regulated Ferroptosis of Cancer Stem Cells. J Am Chem Soc. 2023;145(44):24153\u201365.","journal-title":"J Am Chem Soc"},{"key":"4656_CR61","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jconrel.2024.01.049","volume":"367","author":"XY Zhu","year":"2024","unstructured":"Zhu XY, Wang TY, Jia HR, Wu SY, Gao CZ, Li YH, Zhang X, Shan BH, Wu FG. A ferroptosis-reinforced nanocatalyst enhances chemodynamic therapy through dual H2O2 production and oxidative stress amplification. J Control Release. 2024;367:892\u2013904.","journal-title":"J Control Release"},{"key":"4656_CR62","doi-asserted-by":"publisher","first-page":"114580","DOI":"10.1016\/j.jconrel.2025.114580","volume":"390","author":"L Ga","year":"2026","unstructured":"Ga L, Xin Y, Liu H, Zhang Q, Ning W, Wang X, Yu Y, Su M, Gao H. ROS-amplifying nanoregulators: precision thioredoxin reductase-targeted disruption of redox homeostasis overcomes tumor redox resistance. J Control Release. 2026;390:114580.","journal-title":"J Control Release"},{"issue":"22","key":"4656_CR63","doi-asserted-by":"publisher","first-page":"7763","DOI":"10.1039\/D1SC00929J","volume":"12","author":"YY Xu","year":"2021","unstructured":"Xu YY, Guo YD, Chen L, Ni DL, Hu P, Shi JL. Tumor chemical suffocation therapy by dual respiratory inhibitions. Chem Sci. 2021;12(22):7763\u20139.","journal-title":"Chem Sci"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04656-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04656-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04656-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:02:38Z","timestamp":1788141758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04656-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4656"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04656-z","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving human tissues were approved by the Ethics Committee Board of the Second Affiliated Hospital of Chongqing Medical University (Approval number: 2024\u2009\u2212\u2009800). All procedures involving animals were carried out following the Animal Ethics and Experimental Committee of the Chongqing Medical University and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"819"}}